Diabetes, Vol 45, Issue 5 659-666, Copyright © 1996 by American Diabetes Association

ARTICLES

Oral vanadyl sulfate improves insulin sensitivity in NIDDM but not in obese nondiabetic subjects

M Halberstam, N Cohen, P Shlimovich, L Rossetti and H Shamoon
Department of Medicine, Diabetes Research Center, Albert Einstein College of Medicine, Bronx, NY 10461, USA.

We compared the effects of oral vanadyl sulfate (100 mg/day) in moderately obese NIDDM and nondiabetic subjects. Three-hour euglycemic-hyperinsulinemic (insulin infusion 30 mU / m / min) clamps were performed after 2 weeks of placebo and 3 weeks of vanadyl sulfate treatment in six nondiabetic control subjects (age 37 +/- 3 years; BMI 29.5 +/- 2.4 kg/m2 ) and seven NIDDM subjects (age 53 +/- 2 years; BMI 28.7 +/-1.8 kg/m2). Glucose turnover ([3-3 H]glucose), glycolysis from plasma glucose, glycogen synthesis, and whole-body carbohydrate and lipid oxidation were evaluated. Decreases in fasting plasma glucose (by approximately 1.7 mmol/l) and HbAlc (both P < 0.05) were observed in NIDDM subjects during treatment; plasma glucose was unchanged in control subjects. In the latter, the glucose infusion rate (GIR) required to maintain euglycemia (40.1 +/- 5.7 and 38.1 +/- 4.8 micromol / kg fat-free mass FFM / min) and glucose disposal (Rd) (41.7 +/- 5.7 and 38.9 +/-4.7 micromol / kg FFM / min were similar during placebo and vanadyl sulfate administration, respectively. Hepatic glucose output (HGO) was completely suppressed in both studies. In contrast, in NIDDM subjects, vanadyl sulfate increased GIR approximately 82% (17.3 +/- 4.7 to 30.9 +/- 2.7 micromol / kg FFM / min, P < 0.05); this improvement in insulin sensitivity was due to both augmented stimulation of Rd (26.0 +/-4.0 vs. 33.6 +/- 2.22 micromol / kg FFM / min, P < 0.05) and enhanced suppression of HGO (7.7 +/- 3.1 vs. 1.3 +/- 0.9 micromol / kg FFM / min, P < 0.05). Increased insulin-stimulated glycogen synthesis accounted for >80% of the increased Rd with vanadyl sulfate (P < 0.005), but plasma glucose flux via glycolysis was unchanged. In NIDDM subjects, vanadyl sulfate was also associated with greater suppression of plasma free fatty acids (FFAs) (P < 0.01) and lipid oxidation (P < 0.05) during clamps. The reduction in HGO and increase in Rd were both highly correlated with the decline in plasma FFA concentrations during the clamp period (P < 0.001). In conclusion, small oral doses of vanadyl sulfate do not alter insulin sensitivity in nondiabetic subjects, but it does improve both hepatic and skeletal muscle insulin sensitivity in NIDDM subjects in part by enhancing insulin's inhibitory effect on lipolysis. These data suggest that vanadyl sulfate may improve a defect in insulin signaling specific to NIDDM.
CiteULike    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D.M. Smith, R.M. Pickering, and G.T. Lewith A systematic review of vanadium oral supplements for glycaemic control in type 2 diabetes mellitus QJM, May 1, 2008; 101(5): 351 - 358. [Abstract] [Full Text] [PDF]

				S. Garcia-Vicente, F. Yraola, L. Marti, E. Gonzalez-Munoz, M. J. Garcia-Barrado, C. Canto, A. Abella, S. Bour, R. Artuch, C. Sierra, et al. Oral Insulin-Mimetic Compounds That Act Independently of Insulin Diabetes, February 1, 2007; 56(2): 486 - 493. [Abstract] [Full Text] [PDF]

				G. Y. Yeh, D. M. Eisenberg, T. J. Kaptchuk, and R. S. Phillips Systematic Review of Herbs and Dietary Supplements for Glycemic Control in Diabetes Diabetes Care, April 1, 2003; 26(4): 1277 - 1294. [Abstract] [Full Text] [PDF]

				B. S. O'Connell Select Vitamins and Minerals in the Management of Diabetes Diabetes Spectr, August 1, 2001; 14(3): 133 - 148. [Abstract] [Full Text] [PDF]

				K. Cusi, S. Cukier, R. A. DeFronzo, M. Torres, F. M. Puchulu, and J. C. P. Redondo Vanadyl Sulfate Improves Hepatic and Muscle Insulin Sensitivity in Type 2 Diabetes J. Clin. Endocrinol. Metab., March 1, 2001; 86(3): 1410 - 1417. [Abstract] [Full Text]

				S. Matthaei, M. Stumvoll, M. Kellerer, and H.-U. Häring Pathophysiology and Pharmacological Treatment of Insulin Resistance Endocr. Rev., December 1, 2000; 21(6): 585 - 618. [Abstract] [Full Text]

				I. Goldwaser, S. Qian, E. Gershonov, M. Fridkin, and Y. Shechter Organic Vanadium Chelators Potentiate Vanadium-Evoked Glucose Metabolism In Vitro and In Vivo: Establishing Criteria for Optimal Chelators Mol. Pharmacol., October 1, 2000; 58(4): 738 - 746. [Abstract] [Full Text]

				V. Vuksan, M. P Stavro, J. L Sievenpiper, V. Y. Koo, E. Wong, U. Beljan-Zdravkovic, T. Francis, A. L Jenkins, L. A Leiter, R. G Josse, et al. American Ginseng Improves Glycemia in Individuals with Normal Glucose Tolerance: Effect of Dose and Time Escalation J. Am. Coll. Nutr., June 1, 2000; 19(6): 738 - 744. [Abstract] [Full Text] [PDF]

				G. R. Ehring, H. H. Kerschbaum, C. M. Fanger, C. Eder, H. Rauer, and M. D. Cahalan Vanadate Induces Calcium Signaling, Ca2+ Release-Activated Ca2+ Channel Activation, and Gene Expression in T Lymphocytes and RBL-2H3 Mast Cells Via Thiol Oxidation J. Immunol., January 15, 2000; 164(2): 679 - 687. [Abstract] [Full Text] [PDF]

				I. Goldwaser, J. Li, E. Gershonov, M. Armoni, E. Karnieli, M. Fridkin, and Y. Shechter L-Glutamic Acid gamma -Monohydroxamate. A POTENTIATOR OF VANADIUM-EVOKED GLUCOSE METABOLISM IN VITRO AND IN VIVO J. Biol. Chem., September 10, 1999; 274(37): 26617 - 26624. [Abstract] [Full Text] [PDF]

				B. Lu, D. Ennis, R. Lai, E. Bogdanovic, R. Nikolov, L. Salamon, C. Fantus, H. Le-Tien, and I. G. Fantus Enhanced Sensitivity of Insulin-resistant Adipocytes to Vanadate Is Associated with Oxidative Stress and Decreased Reduction of Vanadate (+5) to Vanadyl (+4) J. Biol. Chem., September 14, 2001; 276(38): 35589 - 35598. [Abstract] [Full Text] [PDF]